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Abstract Because of the increasing incidence, geographic
expansion and economic burden of dengue transmission, den-
gue poses major challenges to policy makers. A vaccine
against dengue is urgently needed, but vaccine development
has been hampered by the lack of an appropriate animal
model, poor understanding of correlates of successful human
immunity, the fear of immune enhancement, and viral inter-
ference in tetravalent combinations. The most suitable target
epitopes for vaccines, as well as the role of nonstructural
proteins remain elusive. The chimeric yellow fever bone-
based live attenuated dengue vaccine is furthest in develop-
ment, but initial efficacy results have been disappointing.
Lessons learnt from this failure will affect the design of future
trials, and increase the urgency to identify the best epitope
and immune correlates. Dengue vaccine introduction
will not be the only strategy to combat dengue, but needs to
be “packaged” with novel vector control approaches, with
community-based interventions to reduce the number of
breeding sites, and reducing the case fatality rate by improving
case management.
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Chimeric dengue vaccine . Efficacy .Monotypic and
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Introduction
The global dengue problem is worsening. Dengue, a
mosquito-borne viral infection, is currently regarded as the
most important arboviral disease internationally, as over 50 %
of the world’s population live in areas where they are at risk of
the disease [1]. Recent mapping of global dengue incidence
suggests that an upper bound total of 3.97 billion people living
in 128 countries are at risk of dengue globally, 824 million in
urban areas and 763 million in periurban areas [2]. Estimates
of the global incidence of dengue infections per year range
between 50 million and 100 million. Accurate numbers are,
however,– lacking due to poor disease surveillance, low levels
of reporting, lack of inexpensive point of care diagnostic tests,
and inconsistent comparative analyses [3•].
Geographic and Numeric Expansion of Dengue
Using cartographic and consensus approaches that include
inapparent and apparent infections, the estimate is closer to
400 million [2, 4••]. Even by more conservative estimates,
dengue has increased 30-fold over the past 50 years [5].
Moreover, it has expanded into new areas. In Europe the first
autochthonous cases were seen in southern France and Croatia
in 2010, and the first major dengue epidemic occurred in
Madeira, south of Portugal, in 2012 [6]. The extent of dengue
in Africa remains unknown, but travelers have unmasked
ongoing dengue outbreaks on several occasions [7–9] and
dengue outbreaks have been reported in more than 22
countries in Africa in the past decade [7]. South East
Asia and the Western Pacific region account for 75 % of the
global dengue disease burden [10]. In the Americas, almost all
countries now have hyperendemicity despite the absence of
dengue in the middle of the 20th century [3•]. In the US, small
outbreaks have occurred in Hawaii, Texas and Florida [11]. In
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international travelers returning from dengue endemic coun-
tries, dengue is now the second most common cause of fever
[12–14]. A recent analysis by the GeoSentinel network, a
global network of travel medicine providers, underpins the
increasing trend of dengue seen in travelers [15•].
Why is dengue expanding so rapidly? The answer is im-
portant for policy makers in order to develop strategies to curb
the problem. But the reasons are complex and involve almost
all facets of modernization and globalization, and may include
factors such as climate change where analyses of the impact
are extremely challenging. Resurgence is most likely due to a
multifactorial metric of unprecedented urbanization associat-
ed with overcrowding and open water sources, changes to the
ecological habitat, lack of vector control, and virus evolution
[16]. Emergence into new areas is mainly due to the increasing
interconnectedness of our world through travel and trade [16,
17]. All these issues pose serious challenges to governments
and policy makers.
Increasing Socioeconomic Burden of Dengue
Dengue is characterized by high morbidity, but relatively low
mortality, and this is one reason why it was neglected for so
many decades. However, global deaths from dengue hemor-
rhagic fever already rank with those from yellow fever in
exceeding combined deaths from all other viral hemorrhagic
fevers, including Ebola, Marburg, Lassa, and Crimean-Congo
[1]. Dengue represents a substantial economic and disease
burden in South East Asia, a burden that is higher than that
of 17 other conditions, including Japanese encephalitis, upper
respiratory infections, and hepatitis B [18]. The estimated
annual burden of dengue is 750,000 disability adjusted life
years (DALYs) [18–21]. In most countries the main burden of
this morbidity and mortality is carried by children [22–25].
Approximately 60 % of this cost is related to indirect or
‘productivity’ losses. In a study in Puerto Rico, hospitalized
patients accounted for 63 % of the cost of dengue illness, and
fatal cases represented an additional 17 % [26]. A study of 12
countries in South East Asia showed an annual economic
burden of US $950 million, with approximately 52 % of these
costs from productivity loss [18]. Dengue illness in the
Americas was estimated to cost $2.1 billion per year on
average (in 2010 US dollars), with a range of $1–4 billion in
sensitivity analyses and substantial year to year variation [21].
Challenges in Vector Control
The main arthropod vector for transmission of the dengue
viruses (DENV) is Aedes aegypti, a mosquito species that is
prevalent in both the tropics and subtropics [27]. The second,
less effective vector, Ae. albopictus, is much more widely
geographically distributed than Ae. aegypti, including in large
parts of the US and southern Europe, but is the less efficient
vector [28, 29]. Significantly, the Aedes mosquitos are pre-
dominantly active during daylight hours, which poses diffi-
culties in controlling the vector–human interaction. The mos-
quito has a high affinity for human blood and high suscepti-
bility to the four DENV serotypes. It is also well adapted to
urban living and thrives in a peridomestic environment close
to humans where it tends to persist because of its limited flight
range [30]. Aedes takes a number of feeds per complete blood
meal, often biting different people, which enhances virus
transmission dynamics. Furthermore, Ae. aegypti distributes
small numbers of eggs among many sites, and this “skip
oviposition” is a driver of dispersal [31]. Skip oviposition also
extends the duration of the gonotrophic cycle. Multiple ovi-
position sites limits the efficacy of attempts to suppress den-
gue transmission by source reduction and “focal” treatments
with aerosols [31]. Innovative approaches that exploit or
negate this behavior are required to ensure effective Ae.
aegypti control. Lastly, another emerging problem is resis-
tance against current standard vector control measures such
as pyrethroids and temephos [32, 33]. Novel vector control
strategies that involve releasingWolbachia-infected mosquitos
or genetically engineered mosquitoes appear promising [34,
35], but their use may be controversial and they are unlikely to
be implemented at a large scale in the near future.
In summary, because of the increasing incidence and geo-
graphic expansion of dengue transmission, increasing socio-
economic burden and currently ineffective control strategies, a
vaccine against dengue is urgently needed. But as discussed
below, vaccine development poses even greater challenges,
not only for scientists and vaccine developers, but also for
policy makers and governments.
Challenges in Dengue Vaccine Development
Dengue vaccines have been in development for over 50 years.
Several vaccine technologies have been applied, including
live attenuated virus, purified inactivated virus, recombinant
subunits, virus-like particles and plasmid or viral vectors.
Each of these approaches has its distinct advantages and
disadvantages, and all are at different stages of development,
as summarized in Table 1. Most of the live attenuated,
inactivated and chimeric live vaccines have gone into clinical
trials. The chimeric vaccine developed by Sanofi Pasteur
(CYD) is the vaccine furthest in development.
Dengue vaccine developers have to aim for a tetravalent
vaccine that provides long-term broad protection against all
four serotypes. But there are major scientific challenges which
have slowed down their development. These include a lack of
an appropriate animal model and a poor knowledge of corre-
lates of successful human immunity to this virus versus
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correlates of immune pathology. Additional complications
include a lack of understanding of the contribution of neutral-
izing antibodies to protection versus other immune mecha-
nisms such as cytotoxic T cell responses, the fear of immune
enhancement, a lack of understanding of the most suitable
target epitopes for vaccines, an unknown role of nonstructural
proteins such as NS1 in dengue immunity, viral interference of
tetravalent combinations, and concern about reactogenicity in
flavivirus-exposed individuals [1]. In the following, the chal-
lenges with regard to DENV per se and immunology are
expanded further as these aspects are most important for
understanding the lack of success so far with the dengue
vaccine candidates with a particular focus on the chimeric
dengue vaccine.
Understanding the Complexity of Dengue Vaccine
Development
DEN virions are composed of a lipid envelope modified by
the insertion of envelope (E) proteins and premembrane/
membrane (prM/M) proteins, with human antibodies mostly
targeted at the E and prM proteins. However, the most suitable
target epitopes for vaccine are still unknown. Anti-E antibod-
ies may have higher type-specific neutralization capacity and
lower ADE potential than anti-prM antibodies. The E protein
of DENV is composed of three domains (EDI, EDII, EDIII)
and is the main target of neutralizing antibodies. Epitopes in
domain III of the E protein is involved in binding of DENV to
cell receptors [36]. But most antibodies are specific for do-
main II of the E protein. Based principally on murine
antidengue responses, ED III is currently still considered an
antigenic target of importance for dengue vaccine develop-
ment, but with more knowledge of E II, this notion may
need to be modified and expanded [37]. Moreover, studies on
human antibody repertoires for dengue have implicated com-
plex conformational epitopes formed by E-protein homodimers
and expressed on whole virions as targets for strongly neutral-
izing antibodies [38••, 39••].
Within each of the four DENV serotypes there are multiple
genetic variations known as genotypes, reflecting the high
degree of mutation and evolutionary pressure. Specific geno-
types may have differences in viral fitness and be associated
with more severe clinical phenotypes. It remains unclear
whether identifying genotypic variation is important in den-
gue vaccine development, but a mismatch between the geno-
typic strains (Asian/American DENV-2 genotype in the vac-
cine strain) and the currently circulating divergent DENV-2
Asian 1 strains has been postulated to explain the low efficacy
in the Thai phase 2b trial of the dengue chimeric vaccine
[40••].
Natural protection against dengue infection is observed as
monotypic, heterotypic and multitypic immunity [41••]. Solid
and presumably life-long protection against reinfection with
Table 1 Approaches to the development of dengue vaccines, and their stages of development
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the same DENVensues following a primary dengue infection,
and this is called monotypic immunity [42]. Heterotypic im-
munity is a short-lived immunity against a new dengue sero-
type infection following a recent dengue infection. In other
words, there is short-lived protection (up to 6 months, but
mostly up to 3 months) in patients convalescing from a recent
dengue infection if they are exposed to infection with another
serotype. The shorter the interval, the greater the protection
[43]. A similar phenomenon was observed on a large scale in
Cuba where the severity of DENV-2 disease in DENV-2
immunes increased as the interval between infections in-
creased from 4 to 20 years [44]. With shorter intervals, het-
erotypic immunity is protective, but with longer intervals it an
increase in severity of disease occurs; a paradoxical challenge
of the immunopathogenesis of dengue. Multitypic immunity
is the notion that sequential dengue infections with more than
two DENV in humans raise neutralizing antibodies to three or
four DENV. Severe disease occurs during the second but not
subsequent heterotypic DENV infections; in other words,
disease severity is suppressed during a third or fourth DENV
infection [41••].
The DENV-specific serum antibody response in humans
consists of a large fraction of cross-reactive, poorly neutraliz-
ing antibodies and a small fraction of serotype-specific, po-
tently inhibitory antibodies [38••]. Recent studies have shown
that humans produce antibodies that neutralize DENV infec-
tion by binding a complex, quaternary structure epitope that is
expressed only when E proteins are assembled on a virus
particle [38••]. Mapping studies indicate that this epitope
spans adjacent E protein dimers and includes the lateral ridge
of domains I and II of the E protein. These results have
significant implications for vaccine development.
The role of NS1 is also still unknown. Dengue NS1 inter-
acts with the complement system and may directly contribute
to the vascular permeability syndrome [41••]. There is an
urgent need to study the role of dengue NS1 in the pathogen-
esis of severe disease and its role as a type-specific protective
immunogen, as such an approach might safely bypass the risk
of antibody-dependent enhancement [41••].
Results from the First Efficacy Trial
Of the many dengue vaccine candidates, only the live-
attenuated tetravalent, chimeric dengue–yellow fever vaccine
developed by Sanofi Pasteur (CYD) has reached phase 2b and
phase 3 clinical trials. This candidate is based on a yellow
fever virus backbone with the yellow fever PrM and E genes
replaced by DENV type-specific preM and E genes. The
results of the phase IIb clinical trial from a single center in
Thailand (CYD 23) were recently released [40••]. In this
observer-masked, randomized, controlled, monocenter, phase
2b, proof-of-concept trial, 4,002 healthy Thai schoolchildren
aged 4 – 11 years were randomly assigned (2:1) to receive
three injections of dengue vaccine or control (rabies vaccine or
placebo) at months 0, 6, and 12. The primary objective was to
assess protective efficacy against virologically confirmed,
symptomatic dengue occurring 1 month or longer after the
third injection (per-protocol analysis). Virologically con-
firmed dengue occurred in 134 children during the study.
Overall efficacy for all four serotypes was 30.2 % and differed
by serotype with the efficacy for DENV-2 being only 9 %,
despite the fact that neutralizing antibodies measured after
doses 2 and 3 showed relatively high mean titers. Why did
the CYD 23 trial show such poor clinical protective efficacy,
particularly against DENV 2?
Halstead offers various hypotheses explaining the observed
poor efficacy [41••]. Interference is a known problem in
tetravalent live vaccine approaches. Interference is a failure
of symmetrical production of neutralizing antibodies to each
of the four DENV serotypes. Simultaneous administration of
tetravalent CYD vaccine produces a hierarchy of immune
response with DENV-4 showing the best response, and
DENV-2 the lowest [42] which could explain the low protec-
tive efficacy against DENV-2. The lack of efficacy can also be
explained by incomplete monotypic immune protection and/
or heterotypic immune function. Heterotypic antibody may
contribute to or prevent development of protective immune
responses. Lastly, Halstead suggests incomplete multitypic
immune protection. The absence of DENV T-cell immunity
in CYD vaccines is the most likely reason for the lack of
multitypic protective immunity, Halstead concludes [41••]. In
addition, Sabchareon et al. hypothesized a mismatch between
the vaccine strain and the genetically divergent circulating
DENV-2 Asian 1 strain [40••].
Lessons Learnt from the CYD 23 Trial
As Halstead writes, “the CYD 23 trial in Thailand is a cau-
tionary tale for investigators designing future dengue vaccine
efficacy trials” [45]. Several lessons can be learned from the
failure of the CYD 23trial.
1. It may have been a wrong assumption that administering
multiple doses of a tetravalent dengue vaccine that result
in broadly cross-reactive DENV-neutralizing antibodies
will provide protection comparable to that of sequential
DENV infections. It is more likely that sequential mono-
typic DENV infections result in a different immune re-
sponse than do sequential doses of a tetravalent vaccine
[41••]. Perhaps a step by step immunization with one or
more attenuated DENV or a prime-boost strategy
would result in the type of protective immunity seen
after sequential infections with two or more wild-type
DENV [41••].
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2. A good in vitro correlate for protection is still elusive, and
this was the biggest set-back in the CYD 23 trial.
The search for in vitro immune correlates of protec-
tion is now on. Halstead suggests to first characterize the
immune responses in a monotypic challenge virus in a
human controlled infection model, and then characterize
the immune responses to monotypic vaccines [41••].
Neutralizing antibodies measured in Vero cells have failed
as a good correlate of protection [46]. Halstead suggests
that neutralizing antibodies could be studied using
primary human monocytes instead [41••]. The use of
a Fc-receptor-bearing cell system as an alternative to
classical neutralization tests to studying vaccine-
induced immunity has also been recommended by
others [47].
3. Little or no attention was paid to the scale or form of the
dengue-specific T-cell responses in the CYD 23 trial. The
absence of DENV T-cell immunity in CYD 23 vaccines is
the best current explanation for the lack of multitypic
protective immunity seen in this trial [41••]. The role of
nonstructural proteins in eliciting cellular immunity
needs to be taken more seriously in other vaccine
approaches. It is plausible that vaccines presenting
yellow fever but not DENV nonstructural protein
antigens such as the CYD vaccine do not mount a
protective dengue T-cell response [41••]. Possibly a
dengue–dengue chimeric vaccine that incorporates
the nonstructural proteins of at least one of the four
serotypes may be successful where the CYD vaccine
failed. Formulations of chimeric dengue vaccine
(DENVax) viruses containing the premembrane and en-
velope genes of serotypes 1–4 expressed in the context of
the attenuated DENV-2 PDK-53 genome have shown
good immunogenicity in animal and early human studies
[48–50]. Currently, Takeda is developing this vaccine
candidate.
4. The CYD 23 trial did not have sufficient numbers of
subjects in whom the prevaccination immune status was
known. It is important to include prevaccination immune
status in future studies to evaluate the serological re-
sponses after vaccination [45]
5. If the hypothesis of Sabchareon et al. holds true about a
mismatch between the vaccine strain and the circulating
Thai strain [40••], then future dengue vaccine candidates
will need to be composed of DENV strains closely
matched to the circulating wild-type strains. If this is the
case, a single dengue vaccine may not be suitable for
global use and new vaccine virus strains will need to be
introduced in response to viral evolution and genotypic
variation [51].
6. Thomas and Endy suggest that a dengue human infection
model (DHIM) should be added in the pathway of vaccine
development [51]. This will not only help in identifying
an immune correlate but also in down-selecting vaccine
candidates, to make early vaccine formulation decisions,
thus avoiding unnecessary costly large-scale trials.
Conclusions: Challenges for Policy Makers and Vaccine
Developers
A large number of diverse dengue vaccine candidates are in
development ensuring continued innovation into the vaccine
pipeline in addition to increasing competition leading to more
affordable vaccines. The absence of an immune correlate of
protection complicates dengue vaccine development efforts
and regulatory strategies. The current vaccine pipeline does
look promising, but major scientific hurdles still need to be
overcome. Next generation dengue vaccines will need to take
into account a favorable product profile including dose-
scheduling, stability and efficacy [37]. Dengue human infec-
tion models will expedite vaccine development, despite their
ethical challenges [51].
More accurate data are needed to inform the prioritization
of research, health policy, and financial resources toward
dengue control. The results of economic evaluations have
often been conflicting because of the use of inconsistent
assumptions. Health economic research specific to dengue is
urgently needed to ensure informed decision making on the
various options for controlling and preventing this disease
[52]. Not only narrowly defined benefit categories such as
healthcare cost savings, care-related productivity gains and
health gains in reduction in morbidity and mortality through
vaccination need to be taken into account, but also broader
scopes such as outcome-related productivity gains, communi-
ty health externalities, and community economic externalities
[53•]. Specifically, the potential effects of dengue vaccination
on outbreak control spending, income from tourism, foreign
direct investment flows, and long-term economic productivity
are important factors to consider in economic evaluations of
dengue vaccination [53•].
TheWorld Health Organization convened a consultation of
experts to develop recommendations and guidelines for long-
term safety assessment of live attenuated dengue vaccines
[54••]. The Live Dengue Vaccines Technical Consultation
Reporting Group has developed a risk-based approach in the
long-term assessment of live dengue vaccines, particularly
beyond the follow-up of subjects in pre-licensure clinical trials
[54••]. They argue for a coordinated approach to developing a
comprehensive and robust post-licensure safety database for
dengue vaccines in parallel with their expanded use. Multiple
stakeholders, including national public health, surveillance
and regulatory authorities, national ethics committees, dengue
vaccine developers, academia, clinicians and international
donors will all need to be included in this coordinated
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approach. Their primary concern is also that severe disease
due to vaccine failure versus vaccine-induced immune en-
hancement of disease are indistinguishable clinically and in
currently available diagnostic assays. Hence benefit–risk as-
sessments will have to rely on epidemiological studies during
and after licensure [54••].
Evidence-informed introduction of vaccines into national
programs, once a dengue vaccine is indeed licensed,
poses another major set of challenges to policy makers.
Governments need to decide upon the epidemiological thresh-
old of dengue activity upon which a national dengue vaccina-
tion program is justified and cost effective. Should only high-
risk groups or the total population be targeted, which age
groups, when should catch-up programs be done? These are
all challenging questions. Given that dengue mostly affects
resource-limited countries, who will bear the massive expense
related to vaccine introduction and to achieve and maintain
high vaccination coverage? Changing the perception of den-
gue in non-endemic countries to help generate global support
for dengue vaccination is paramount [55]. With the introduc-
tion of an effective vaccine, dengue is a disease that could be
controlled, which means that in order to ensure a vaccine is
introduced as rapidly as possible, there is a need to start
preparing now [55].
Governments of countries that are currently unaffected by
dengue need to be alert to the introduction of DENV via
travelers and the emergence of autochthonous cases which
can occur any time, in particular in countries where either
Ae. aegypti or Ae. albopictus exist and where climate
and ecological conditions are favorable [56]. The recent
major dengue outbreak in Madeira, Portugal, only underlines
this threat [57].
Mathematical models may enhance the understanding of
population-wide dengue strategies, and can assess multiple
intervention packages. Dengue vaccine introduction will in
itself not be the only strategy to combat dengue. It needs to be
a “public health package” that includes vector control,
community-based interventions to reduce breeding sites, in-
creasing the scope and breadth of surveillance, reducing the
case fatality rate by improving case management, and perhaps
novel entomological approaches to reducing transmission by
altering mosquito ecology or genetics [58•]. TheWorld Health
Organization recommends further research into novel and
community-based effective vector control interventions that
correspond with the ‘Global Strategic Framework for
Integrated Vector Management’ (IVM) of vector-borne dis-
eases such as dengue [27, 59, 60]. An international
multisectorial response, such as that outlined in the WHO
Global Strategy for Dengue Prevention and Control, 2012–
2020 [61], is now essential. To this end, the Partnership of
Dengue Control (PDC) is a new organization led by Gubler
that aims to utilize global expertise and resources for dengue
control. Working closely with WHO on the Global Strategy
for Dengue Control, the PDC’s goal is to accelerate innovation
in vaccination, vector control, antiviral treatment, clinical man-
agement, diagnostics, surveillance, and social mobilization.
Compliance with Ethics Guidelines
Conflict of Interest Paul MacAry declares no conflicts of interest.
Annelies Wilder-Smith received grants, honoraria and travel expenses
reimbursed from Sanofi Pasteur, GSK and Novartis.
Human and Animal Rights and Informed Consent This article does
not contain any studies with human or animal subjects performed by the
author.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Wilder-Smith A, Ooi EE, Vasudevan SG, Gubler DJ. Update on
dengue: epidemiology, virus evolution, antiviral drugs, and vaccine
development. Curr Infect Dis Rep. 2010;12:157–64.
2. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS,
et al. Refining the global spatial limits of dengue virus
transmission by evidence-based consensus. PLoS Negl Trop
Dis. 2012;6:e1760.
3.• Murray NE, QuamMB,Wilder-Smith A. Epidemiology of dengue:
past, present and future prospects. Clin Epidemiol. 2013;5:299–
309. Comprehensive overview of dengue with historical aspects
and future predictions, including deliberations on the reasons for
the upsurge of dengue.
4.•• Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, et al. The
global distribution and burden of dengue. Nature. 2013;496:504–7.
Most recent update on estimates on dengue globally using a com-
plex approach based on expert consensus, web-based tools, publi-
cations and reports, travelers and public sources.
5. WHO. Dengue: guidelines for diagnosis, treatment, prevention and
control. Geneva: World Health Organization; 2009.
6. Tomasello D, Schlagenhauf P. Chikungunya and dengue autoch-
thonous cases in Europe, 2007-2012. Travel Med Infect Dis.
2013;11:274–84.
7. Amarasinghe A, Kuritsk JN, Letson GW, Margolis HS. Dengue
virus infection in Africa. Emerg Infect Dis. 2011;17:1349–54.
8. Sessions OM,Khan K, HouY,Meltzer E, QuamM, et al. Exploring
the origin and potential for spread of the 2013 dengue outbreak in
Luanda, Angola. Glob Health Action. 2013;6:21822.
9. Ninove L, Parola P, Baronti C, De Lamballerie X, Gautret P, et al.
Dengue virus type 3 infection in traveler returning from west
Africa. Emerg Infect Dis. 2009;15:1871–2.
10. WHO. Situation update of dengue in the SEA region, 2010. New
Delhi: World Health Organization Regional Office for South-East
Asia. http://209.61.208.233/LinkFiles/Dengue_Dengue_update_
SEA_2010.pdf. Accessed 27 March 2014.
404, Page 6 of 8 Curr Infect Dis Rep (2014) 16:404
11. Ferreira GL. Global dengue epidemiology trends. Rev Inst Med
Trop Sao Paulo. 2012;54 Suppl 18:S5–6.
12. Wilson ME, Weld LH, Boggild A, Keystone JS, Kain KC, et al.
Fever in returned travelers: results from the GeoSentinel
Surveillance Network. Clin Infect Dis. 2007;44:1560–8.
13. Schwartz E, Weld LH, Wilder-Smith A, von Sonnenburg F,
Keystone JS, et al. Seasonality, annual trends, and characteristics
of dengue among ill returned travelers, 1997-2006. Emerg Infect
Dis. 2008;14:1081–8.
14. Wilder-Smith A, Schwartz E. Dengue in travelers. N Engl J Med.
2005;353:924–32.
15.• Leder K, Torresi J, Brownstein JS, Wilson ME, Keystone JS, et al.
Travel-associated illness trends and clusters, 2000-2010. Emerg
Infect Dis. 2013;19:1049–73. This is the most comprehensive recent
analysis of data from tens of thousands of returning travelers
globally to describe trends and relative importance of infections
acquired by travel.
16. Wilder-Smith A, Gubler DJ. Geographic expansion of dengue: the
impact of international travel. Med Clin North Am. 2008;92:1377–90.
17. Tatem AJ, Huang Z, Das A, Qi Q, Roth J, et al. Air travel and
vector-borne disease movement. Parasitology. 2012;139:1816–30.
18. ShepardDS,Undurraga EA,HalasaYA. Economic and disease burden
of dengue in southeast Asia. PLoS Negl Trop Dis. 2013;7:e2055.
19. Gubler DJ. The global emergence/resurgence of arboviral diseases
as public health problems. Arch Med Res. 2002;33:330–42.
20. BeattyME, Letson GW,Margolis HS. Estimating the global burden
of dengue. In: Abstract book: Dengue 2008. The Second
International Conference on Dengue and Dengue Haemorrhagic
Fever. Phuket, Thailand. 17–19 Oct 2008. (As cited in: Gubler
DJ. Dengue, urbanization and globalization: the unholy trinity of
the 21st century. Trop Med Health. 2011;39(4 Suppl):3–11.
21. Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH.
Economic impact of dengue illness in the Americas. Am J Trop
Med Hyg. 2011;84:200–7.
22. Hammond SN, Balmaseda A, Perez L, Tellez Y, Saborio SI, et al.
Differences in dengue severity in infants, children, and adults in a 3-
year hospital-based study in Nicaragua. Am J Trop Med Hyg.
2005;73:1063–70.
23. Egger JR, Coleman PG. Age and clinical dengue illness. Emerg
Infect Dis. 2007;13:924–5.
24. Kittigul L, Pitakarnjanakul P, Sujirarat D, Siripanichgon K. The
differences of clinical manifestations and laboratory findings in
children and adults with dengue virus infection. J Clin Virol.
2007;39:76–81.
25. Guzman MG, Kouri G, Bravo J, Valdes L, Vazquez S, et al. Effect
of age on outcome of secondary dengue 2 infections. Int J Infect
Dis. 2002;6:118–24.
26. Halasa YA, Shepard DS, Zeng W. Economic cost of dengue in
Puerto Rico. Am J Trop Med Hyg. 2012;86:745–52.
27. WHO. Dengue: guidelines for diagnosis, treatment, prevention and
control – new edition. Geneva:World Health Organization; 2009. p.
147.
28. Reiter P. Aedes albopictus and the world trade in used tires, 1988-
1995: the shape of things to come? J Am Mosq Control Assoc.
1998;14:83–94.
29. Reiter P. Yellow fever and dengue: a threat to Europe? Euro
Surveill. 2010;15:19509.
30. Morrison AC, Zielinski-Gutierrez E, Scott TW, Rosenberg R.
Defining challenges and proposing solutions for control of the virus
vector Aedes aegypti. PLoS Med. 2008;5:e68.
31. Reiter P. Oviposition, dispersal, and survival in Aedes aegypti:
implications for the efficacy of control strategies. Vector Borne
Zoonotic Dis. 2007;7:261–73.
32. McAllister JC, Godsey MS, Scott ML. Pyrethroid resistance in
Aedes aegypti and Aedes albopictus from Port-au-Prince, Haiti. J
Vector Ecol. 2012;37:325–32.
33. Mulyatno KC, Yamanaka A. Ngadino, Konishi E. Resistance of
Aedes aegypti (L.) larvae to temephos in Surabaya, Indonesia.
Southeast Asian J Trop Med Public Health. 2012;43:29–33.
34. Alphey N, Alphey L, Bonsall MB. A model framework to estimate
impact and cost of genetics-based sterile insect methods for dengue
vector control. PLoS One. 2011;6:e25384.
35. Walker T, Johnson PH,Moreira LA, Iturbe-Ormaetxe I, Frentiu FD,
et al. The wMel Wolbachia strain blocks dengue and invades caged
Aedes aegypti populations. Nature. 2011;476:450–3.
36. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli
L, et al. The human immune response to Dengue virus is dominated
by highly cross-reactive antibodies endowed with neutralizing and
enhancing activity. Cell Host Microbe. 2010;8:271–83.
37. Schmitz J, Roehrig J, Barrett A, Hombach J. Next generation
dengue vaccines: a review of candidates in preclinical development.
Vaccine. 2011;29:7276–84.
38.•• de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, et al.
Identification of human neutralizing antibodies that bind to complex
epitopes on dengue virions. Proc Natl Acad Sci U S A. 2012;109:
7439–44. Very important paper explaining the new thinking on
complex epitopes and the quaternary structure.
39.•• Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, et al. The
structural basis for serotype-specific neutralization of dengue
virus by a human antibody. Sci Transl Med. 2012;4:139ra183.
This paper explains why the chimeric dengue vaccine may have
failed.
40.•• Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K,
Chanthavanich P, et al. Protective efficacy of the recombinant, live-
attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren:
a randomised, controlled phase 2b trial. Lancet. 2012;380:1559–67.
Pivotal efficacy trial in Thailand that showed poor efficacy of the
chimeric CYD vaccine.
41.•• Halstead SB. Identifying protective dengue vaccines: guide to master-
ing an empirical process. Vaccine. 2013;31:4501–7. Most important
paper on the scientific challenges of dengue vaccine development
which formed the basis for many of the conclusions made in this
review.
42. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, et al.
Viremia and immunogenicity in nonhuman primates of a tetravalent
yellow fever-dengue chimeric vaccine: genetic reconstructions,
dose adjustment, and antibody responses against wild-type dengue
virus isolates. Virology. 2002;298:146–59.
43. Sabin AB. Research on dengue during World War II. Am J Trop
Med Hyg. 1952;1:30–50.
44. GuzmanMG, Kouri G, Valdes L, Bravo J, Vazquez S, Halstead SB.
Enhanced severity of secondary dengue-2 infections: death rates in
1981 and 1997 Cuban outbreaks. Rev Panam Salud Publ. 2002;11:
223–7.
45. Halstead SB. Dengue vaccine development: a 75 % solution?
Lancet. 2012;380:1535–6.
46. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, et al.
Relationship of preexisting dengue virus (DV) neutralizing anti-
body levels to viremia and severity of disease in a prospective
cohort study of DV infection in Thailand. J Infect Dis. 2004;189:
990–1000.
47. Moi ML, Takasaki T. Kurane I Efficacy of tetravalent dengue
vaccine in Thai schoolchildren. Lancet. 2013;381:1094.
48. Brewoo JN, Kinney RM, Powell TD, Arguello JJ, Silengo SJ, et al.
Immunogenicity and efficacy of chimeric dengue vaccine
(DENVax) formulations in interferon-deficient AG129 mice.
Vaccine. 2012;30:1513–20.
49. Osorio JE, Brewoo JN, Silengo SJ, Arguello J, Moldovan IR, et al.
Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in
Cynomolgus macaques. Am J Trop Med Hyg. 2011;84:978–87.
50. Osorio JE, Huang CY, Kinney RM. Stinchcomb DT Development
of DENVax: a chimeric dengue-2 PDK-53-based tetravalent
Curr Infect Dis Rep (2014) 16:404 Page 7 of 8, 404
vaccine for protection against dengue fever. Vaccine. 2011;29:
7251–60.
51. Thomas SJ, Endy TP. Current issues in dengue vaccination. Curr
Opin Infect Dis. 2013;26:429–34.
52. Beatty ME, Beutels P, Meltzer MI, Shepard DS, Hombach J, et al.
Health economics of dengue: a systematic literature review and
expert panel’s assessment. Am J Trop Med Hyg. 2011;84:473–88.
53.• Barnighausen T, Bloom DE, Cafiero ET, O'Brien JC. Valuing the
broader benefits of dengue vaccination,with a preliminary application
to Brazil. Semin Immunol. 2013;25:104–13. Interesting review and
analysis of the complexity of economic evaluation of dengue vaccines.
54.•• Live Dengue Vaccines Technical Consultation Reporting Group,
Bentsi-Enchill AD, Schmitz J, Edelman R, Durbin A, et al. Long-
term safety assessment of live attenuated tetravalent dengue vac-
cines: deliberations from a WHO technical consultation. Vaccine.
2013;31:2603–9.Excellent summary of the issues and challenges in
the use of live attenuated dengue vaccines.
55. Lam SK, Burke D, Capeding MR, Chong CK, Coudeville L, et al.
Preparing for introduction of a dengue vaccine: recommendations
from the 1st Dengue v2VAsia-Pacific Meeting. Vaccine. 2011;29:
9417–22.
56. Liu-Helmersson J, Stenlund H, Wilder-Smith A, Rocklov J.
Vectorial capacity of Aedes aegypti: effects of temperature and
implications for global dengue epidemic potential. PLoS One.
2014;9:e89783.
57. Wilder-Smith A, QuamM, Sessions O, Rocklov J, Liu-Helmersson
J, et al. The dengue outbreak in Madeira 2012: exploring the
origins. Euro Surveill 2014;19(8). Available online: http://www.
eurosurveillance.org/ViewArticle.aspx?ArticleId=20718.
58.• WHO-VMI Dengue VaccineModeling Group, Beatty M, BoniMF,
Brown S, Buathong R, et al. Assessing the potential of a candidate
dengue vaccine with mathematical modeling. PLoS Negl Trop Dis.
2012;6:e1450. Important paper explaining the complex issues
around the introduction of dengue vaccines.
59. WHO. Comprehensive guidelines for prevention and control of
dengue and dengue haemorrhagic fever, revised and expanded
edition. New Delhi: World Health Organization South East Asia
Regional Office; 2011.
60. WHO. Neglected tropical diseases – integrated vector management.
Geneva: World Health Organization; 2012.
61. WHO. Global strategy for dengue prevention and control, 2012-
2020. Geneva: World Health Organization; 2012.
404, Page 8 of 8 Curr Infect Dis Rep (2014) 16:404
